<div id="readability-page-1"><div> By Katherine Hamilton <pre></pre> MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories. The stock advanced 7% to $13.14 in pre-market trading Wednesday. The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected. Revenue growth was driven by a 22% increase in international sales. MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems. The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems. <pre></pre> Write to Katherine Hamilton at katherine.hamilton@wsj.com <pre></pre> (END) Dow Jones Newswires June 03, 2026 09:49 ET (13:49 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

MMED

雅培

MiniMed 的股票在盤前交易中上漲了 7%，達到 13.14 美元，此前公司報告第四季度營收為 8.37 億美元，超出預期。增長主要得益於國際銷售增長 22%。此外，MiniMed 還擴大了與雅培的合作伙伴關係，以商業化其智能給藥系統的葡萄糖 - 酮傳感器

MiniMed 股價因第四季度銷售增長及與雅培合作伙伴關係的擴展而上漲